Page 43 - CIBEROBN2016-ENG

• Study of the physiological mechanisms responsible for the regulation of energy balance in the gastrointestinal tract. Role of ghrelin nesfatin a-1, gastricendogenous cannabinoid, signaling pathway activated by FNDC5 andmTOR/S6k1.
• Study of the effect of lactation on metabolism. Study of lipid metabolism in adipose tissue and gastrointestinal mechanisms.
Most relevant scientific articles
• Fagundo A.B., Jiménez-Murcia S., Giner-Bartolomé C., Aguera Z., Sauchelli S., Pardo M. et al. Modulation of irisin and physical activity on executive functions in obesity and morbid obesity. Scientific Reports. 2016;6.
• Barja-Fernández S., Folgueira C., Castelao C., Al-Massadi O., Bravo S.B., García-Caballero T. et al. FNDC5 is produced in the stomach and associated to body composition. Scientific Reports. 2016;6.
• Zhou B., Lu Y., Hajifathalian K., Bentham J., Di Cesare M., Danaei G. et al. Worldwide trends in diabetes since 1980: A pooled analysis of 751 population-based studies with 4.4 million participants. The Lancet. 2016;387(10027).
• Di Cesare M., Bentham J., Stevens G.A., Zhou B., Danaei G., Lu Y. et al. Trends in adult body-mass index in 200 countries from 1975 to 2014: A pooled analysis of 1698 population-based measurement studies with 19.2 million participants. The Lancet. 2016;387(10026):1377-1396.
• Díaz-Lagares A., Méndez-González J., Hervás D., Saigi M., Pajares M.J., García D. et al. A novel epigenetic signature for early diagnosis in lung cancer. Clinical Cancer Research. 2016;22(13):3361-3371.
Hightlights
The research group has published 51 articles with a cumulative impact factor in them of 250,60. Has managed 2 new clinical trials. It is also worth mentioning the development of a project financed by the FEDER-INNTERCONECTA concerning nutritional intervention with products developed from mushrooms and fish on the evolution of patients with pre-diabetic metabolic syndrome.
Implementation of a platform within the CIBER for the study of epigenetics in cancer and obesity. The main objective of this platform is the use of high-throughput epigenomic technology for research and clinical practice on metabolic pathologies and cancer. In addition, it will lend support to different lines of research within and outside the IDIS in the implementation of epigenetic approaches, both in the research of new mechanisms involved in the pathogenesis and in new biomarkers involved in diagnostic, prognostic and response to the treatment of complex diseases with great relevance in our society.
Has developed research focused on the search for new effective therapies against obesity based on
oral treatments with antioxidants whose results will be published soon. A regional multidisciplinary consortium has also been created for the search of therapies against various diseases (obesity, cancer and neurodegenerative diseases) based on the development of nanostructures.
In the project The Obesity Paradox, with an overall balance of 7 articles already submitted for publication. Obtainment of a new research project of the ISCIII and has requested a new European Patent Application.
OBN
Research groups 43